Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) have been assigned a consensus rating of “Hold” from the eleven ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and five have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $7.03.

A number of equities research analysts have recently commented on ADAP shares. ValuEngine upgraded shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. BidaskClub cut shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, July 26th. Guggenheim cut shares of Adaptimmune Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, August 1st. Zacks Investment Research cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. Finally, Roth Capital initiated coverage on shares of Adaptimmune Therapeutics in a research report on Friday, May 31st. They issued a “buy” rating and a $7.00 target price on the stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Adaptimmune Therapeutics by 8.7% in the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 28,621 shares of the biotechnology company’s stock worth $123,000 after acquiring an additional 2,280 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Adaptimmune Therapeutics by 25.7% in the second quarter. SG Americas Securities LLC now owns 23,259 shares of the biotechnology company’s stock worth $94,000 after acquiring an additional 4,752 shares during the last quarter. Bamco Inc. NY boosted its position in shares of Adaptimmune Therapeutics by 6.1% in the second quarter. Bamco Inc. NY now owns 172,669 shares of the biotechnology company’s stock worth $694,000 after acquiring an additional 10,000 shares during the last quarter. Aperio Group LLC acquired a new stake in shares of Adaptimmune Therapeutics in the second quarter worth approximately $88,000. Finally, Acadian Asset Management LLC boosted its position in shares of Adaptimmune Therapeutics by 119.5% in the second quarter. Acadian Asset Management LLC now owns 42,517 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 23,143 shares during the last quarter. 65.15% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ ADAP traded down $0.01 during midday trading on Friday, reaching $1.93. 150,833 shares of the stock were exchanged, compared to its average volume of 301,403. The company has a market capitalization of $177.98 million, a P/E ratio of -2.01 and a beta of 1.79. Adaptimmune Therapeutics has a 52-week low of $1.37 and a 52-week high of $14.54. The company has a current ratio of 6.19, a quick ratio of 6.19 and a debt-to-equity ratio of 0.13. The stock has a 50 day moving average price of $2.00 and a 200-day moving average price of $3.50.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.07). The firm had revenue of $0.16 million for the quarter, compared to analysts’ expectations of $4.25 million. Adaptimmune Therapeutics had a negative return on equity of 42.78% and a negative net margin of 161.09%. On average, analysts forecast that Adaptimmune Therapeutics will post -1.28 earnings per share for the current year.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Further Reading: What is a Stop Order?

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.